Mechanism of Action of Naltrexone
Naltrexone is a competitive opioid receptor antagonist that works by blocking mu, kappa, and delta opioid receptors, thereby preventing opioids and endogenous opioid peptides from binding and exerting their effects. 1
Primary Mechanism: Opioid Receptor Antagonism
Naltrexone functions as a pure opioid antagonist through competitive binding at opioid receptors, with highest affinity for mu-opioid receptors. 2 This competitive inhibition is analogous to competitive enzyme inhibition, meaning the blockade is potentially surmountable with very high doses of opioids (though this can result in excessive histamine release). 1
Key Pharmacologic Properties:
Naltrexone is derived from oxymorphine through substitution of the N-methyl group with a methylcyclopropyl group, creating a semisynthetic competitive antagonist. 2
The drug markedly attenuates or completely blocks the subjective effects of intravenously administered opioids in a reversible manner. 1
Clinical studies demonstrate that 50 mg of naltrexone blocks the pharmacologic effects of 25 mg of intravenous heroin for up to 24 hours, with doubling the dose providing 48-hour blockade and tripling providing approximately 72-hour blockade. 1
Mechanism in Alcohol Use Disorder
While naltrexone's mechanism in treating alcoholism is not fully understood, it is believed to involve blockade of endogenous opioid systems that mediate alcohol's rewarding effects. 1 The drug competitively binds to opioid receptors and blocks the effects of endogenous opioids that may be involved in alcohol's positively reinforcing effects and conditioned anticipation of these effects. 3
Naltrexone reduces alcohol consumption by decreasing the reward associated with drinking, rather than through aversive therapy or disulfiram-like reactions. 1, 4
The majority (70%) of clinical trials measuring "heavy or excessive drinking" demonstrated advantages for naltrexone over placebo, compared to only 36% of trials measuring abstinence or "any drinking." 4
Additional Mechanisms: Reward Pathway Modulation
Naltrexone may reset the reward pathway through an opponent process mechanism, though this is less well-characterized than its direct receptor antagonism. 2
Low-Dose Naltrexone (LDN) Mechanisms:
At lower doses (1-5 mg), naltrexone transiently blocks opioid receptors, resulting in compensatory increased ligand and receptor expression that favors kappa over mu receptors. 5 This leads to:
- Decreased inflammatory mediators and reduced itch sensation 5
- Antagonism of non-opioid receptors, including the pro-inflammatory toll-like receptor 4 (TLR-4) 5
Pharmacokinetic Considerations
Naltrexone has a plasma half-life of 4 hours, but its active metabolite 6-β-naltrexol has a half-life of 13 hours. 2 This metabolite accumulates during long-term therapy, and antagonist effects may persist for 2-3 days after stopping oral naltrexone. 2
The drug undergoes extensive first-pass metabolism with oral bioavailability of only 5-40%, though it is well absorbed (96% from the gastrointestinal tract). 1
Systemic clearance (
3.5 L/min) exceeds liver blood flow (1.2 L/min), indicating >98% metabolism and suggesting extrahepatic sites of drug metabolism exist. 1
Clinical Implications of Mechanism
Naltrexone has few intrinsic actions besides its opioid blocking properties, though it does produce some pupillary constriction by an unknown mechanism. 1
The drug does not cause tolerance or dependence with chronic administration. 1
In opioid-dependent individuals, naltrexone will precipitate withdrawal symptoms due to its competitive displacement of opioids from receptors. 2
Extended-release formulations may cause up-regulation of opiate receptors during long-term maintenance therapy, potentially affecting perioperative opioid requirements. 2